Is 3-hour cyclosporine blood level superior to trough level in early post-renal transplantation period?

Journal of Urology

Volumn 163, Issue 1, 2000, Pages 37-41

  Mahalati, Kamran ^a   Lawen, Joseph ^a   Kiberd, Bryce ^a   Belitsky, Philip ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Cyclosporine; Drug monitoring; Kidney; Kidney transplantation; Rejection

Indexed keywords

CYCLOSPORIN; HLA ANTIGEN;

ADULT; ARTICLE; DRUG BLOOD LEVEL; DRUG MONITORING; FEMALE; GRAFT REJECTION; HUMAN; HUMAN TISSUE; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MICROEMULSION; NEPHROTOXICITY; PRIORITY JOURNAL;

EID: 0033992074     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)67967-0     Document Type: Article

References (18)

1. Nankivell, B. J., Hibbins, M. and Chapman, J. R.: Diagnostic utility of whole blood cyclosporine measurements in renal transplantation using triple therapy. Transplantation, 58: 989, 1994.
2. Oellerich, M., Armstrong, V. W., Kahan, B. et al: Lake Louise consensus conference on cyclosporine monitoring in organ transplantation: report of the consensus panel. Ther Drug Monit, 17: 642, 1995.
3. Lindholm, A. and Kahan, B. D.: Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation. Clin Pharmacol Ther, 54: 205, 1993.
4. Senel, M. F., Van Buren, C. T., Welsh, M. et al: Impact of early cyclosporin average blood concentration on early kidney transplant failure. Transplant Int, 11: 46, 1998.
5. Kovarik, J. M., Mueller, E. A. and Niese, D.; Clinical development of a cyclosporine microemulsion in transplantation. Ther Drug Monit, 18: 429, 1996.
6. Holt, D. W., Mueller, E A., Kovarik, J. M. et al: The pharmacokinetics of Sandimmun Neoral: a new oral formulation of cyclosporine. Transplant Proc, 26: 2935, 1994.
7. Barone, G., Chang, C. T., Choc, M. G., Jr. et al: The pharmacokinetics of a microemulsion formulation of cyclosporine in primary renal allograft recipients. The Neoral Study Group. Transplantation, 61: 875, 1996.
8. Niese, D.: A double-blind randomized study of Sandimmun Neoral versus Sandimmun in new renal transplant recipients: results after 12 months. The International Sandimmun Neoral Study Group. Transplant Proc, 27: 1849, 1995.
9. Lodge, J. P. and Pollard, S. G.: Neoral vs Sandimmun: interim results of a randomized trial of efficacy and safety in preventing acute rejection in new renal transplant recipients. Transplant Proc, 29: 272, 1997.
10. Barone, G., Bunke, C. M., Choc, M. G. et al: The safety and tolerability of cyclosporine emulsion versus cyclosporine in a randomized, double-blind comparison in primary renal allograft recipients. The Neoral Study Group. Transplantation, 61: 968, 1996.
11. Cantarovich, M., Latter, D. and Fitchett, D.: Comparison of cyclosporine monitoring with trough levels to levels obtained 6 hours after the morning dose in heart transplant patients: a prospective randomized study. Transplant Proc, 29: 602, 1997.
12. Cantarovich, M., Besner, J. G., Barkun, J. S. et al: Two-hour cyclosporine level determination is the appropriate tool to monitor Neoral therapy. Clin Transplant, 12: 243, 1998.
13. Cantarovich, M., Barkun, J. S., Tchervenkov, J. I. et al: Comparison of Neoral dose monitoring with cyclosporine trough levels versus 2-hour postdose levels in stable liver transplant patients. Transplantation, 66: 1621, 1998.
14. Canadian Liver Transplant Study Group. Importance of cyclosporine pharmacokinetics to clinical outcomes after liver transplantation. Transplant Proc, 30: 1826, 1998.
15. Meyer, M. M., Munar, M., Udeaja, J. et al: Efficacy of area under the curve cyclosporine monitoring in renal transplantation. J Am Soc Nephrol, 4: 1306, 1993.
16. Kasiske, B. L., Heim-Duthoy, K., Rao, K. V. et al: The relationship between cyclosporine pharmacokinetic parameters and subsequent acute rejection in renal transplant recipients. Transplantation, 46: 716, 1998.
17. Mahalati, K., Belitsky, P., Sketris, I. et al: Neoral monitoring by simplified sparse sampling area under the concentration-time curve: its relationship to acute rejection and cyclosporine nephrotoxicity early after kidney transplantation. Transplantation, 68: 55, 1999.
18. max) correlate with freedom from liver graft rejection: results of a prospective randomized comparison of Neoral and sandimmune for liver transplantation (NOF-8). Transplantation, 67: 1133, 1999.